Biotechnology The skeptic: What precision medicine revolution? The benefits of genomic drugs are exaggerated, hurting patients and the practice of medicine, says one high-profile oncologist. by Stephen S. Hall 2018-10-23T05:00:00-04:00
Rewriting Life A Cancer “Atlas” to Predict How Patients Will Fare Researchers use a big-data approach to find links between different genes and patient survival. by Emily Mullin 2017-08-17T15:43:00-04:00
Business Impact Will Science Have a Seat at President Trump’s Table? Every president since FDR has had a science advisor. Trump has yet to name one or indicate leading candidates. by Mike Orcutt 2017-01-17T00:00:00-05:00
Business Impact Slow Progress to Better Medicine Thirteen years after the human genome was sequenced, some remarkable treatments are being developed. by Nanette Byrnes 2016-07-25T00:00:00-04:00
Business Impact Inside Genomics Pioneer Craig Venter’s Latest Production His startup is using data to unlock the connections between DNA and illness. by Arlene Weintraub 2016-07-25T00:00:00-04:00
Rewriting Life Biotech Makes Personalized Cancer Vaccines Using Tumor Samples Training immune cells with genes harvested from a patient’s own tumor could make an already promising new cancer treatment even better. by Susan Young Rojahn 2014-06-10T00:00:00-04:00
Rewriting Life Finding Cancer Cells in the Blood Technologies that can pull tumor cells from patients’ blood are giving researchers an unprecedented look at cancer. by Susan Young Rojahn 2013-07-16T00:00:00-04:00
Rewriting Life Human Embryonic Stem Cells Cloned Scientists produced embryonic stem cells from the DNA of one person combined with a human donor egg. by Susan Young Rojahn 2013-05-15T17:07:23-04:00
Rewriting Life Genomic Study Spots Which Tumors Are Deadliest Genomics signatures in uterine cancers could offer clues to prognosis. by Susan Young Rojahn 2013-05-01T15:15:00-04:00
Rewriting Life Questions over Gene Patents Shake Diagnostics Industry The impending Supreme Court ruling on gene patents is creating uncertainty in the molecular diagnostics sector. by Susan Young Rojahn 2013-04-24T00:00:00-04:00
